Abstract
This review summarises ongoing developments in personalised medicine and individualised medicine in chronic obstructive pulmonary disease (COPD). Currently applied classification systems largely ignore the complexity and heterogeneity of the COPD syndrome. Personalised medicine has to consider the influence of unique circumstances of the person, which contribute to this heterogeneity and complexity. Pulmonary rehabilitation is described as a comprehensive, individualised intervention based on thorough assessment of identifiable treatable traits. Partnership in care will become a crucial factor to improve and maintain health. Tolerating uncertainty and unpredictability will enrich future doctor–patient relationships.
Abstract
Pulmonary rehabilitation offers an integrated approach for personalised management of patients with COPD http://ow.ly/Hyog30irp1h
Footnotes
Number 5 in the Series “Personalised medicine in respiratory diseases” Edited by Renaud Louis and Nicolas Roche
Previous articles in this series: No. 1: Chung KF. Personalised medicine in asthma: time for action. Eur Respir Rev 2017; 26: 170064. No. 2: Bonsignore MR, Suarez Giron MC, Marrone O, et al. Personalised medicine in sleep respiratory disorders: focus on obstructive sleep apnoea diagnosis and treatment. Eur Respir Rev 2017; 26: 170069. No. 3: Mascaux C, Tomasini P, Greillier L, et al. Personalised medicine for nonsmall cell lung cancer. Eur Respir Rev 2017; 26: 170066. No. 4: Noell G, Faner R, Agusti A. From systems biology to P4 medicine: applications in respiratory medicine. Eur Respir Rev 2018; 27: 170110.
Conflict of interest: E.F.M. Wouters is a board member for Nycomed and Boehringer Ingelheim. He has received grants from AstraZeneca and GSK, and has received speakers’ fees from AstraZeneca, GlaxoSmithKline, Novartis and Chiesi.
Provenance: Commissioned article, peer reviewed.
- Received November 15, 2017.
- Accepted February 12, 2018.
- Copyright ©ERS 2018.
ERR articles are open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.